Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.

Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Fisher J, Desideri S, He X, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) Consortium.

J Neurooncol. 2010 Nov;100(2):261-8. doi: 10.1007/s11060-010-0190-0. Epub 2010 May 7. Erratum in: J Neurooncol. 2010 Nov;100(2):269. Mikkelson, Tom [corrected to Mikkelsen, Tom].

2.

Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG; New Approaches to Brain Tumor Therapy CNS Consortium.

Neuro Oncol. 2008 Aug;10(4):608-16. doi: 10.1215/15228517-2008-030. Epub 2008 Jun 24.

3.

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD.

J Clin Oncol. 2006 Aug 1;24(22):3651-6.

PMID:
16877733
4.

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M.

J Clin Oncol. 2005 Sep 20;23(27):6647-56.

PMID:
16170172
5.

A phase I/II trial of vandetanib for patients with recurrent malignant glioma.

Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA.

Neuro Oncol. 2012 Dec;14(12):1519-26. doi: 10.1093/neuonc/nos265. Epub 2012 Oct 25.

6.

A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.

Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA.

Neuro Oncol. 2010 Feb;12(2):181-9. doi: 10.1093/neuonc/nop042. Epub 2010 Jan 22.

7.

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS.

Cancer. 2005 Jan 15;103(2):329-38.

8.

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.

Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8.

9.

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD.

Clin Cancer Res. 2006 Aug 15;12(16):4899-907.

10.

Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.

Shimizu T, Yamamoto N, Yamada Y, Fujisaka Y, Yamada K, Fujiwara Y, Takayama K, Tokudome T, Klimovsky J, Tamura T.

Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8. Epub 2007 Jun 27.

PMID:
17594093
11.

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.

Stupp R, Tosoni A, Bromberg JE, Hau P, Campone M, Gijtenbeek J, Frenay M, Breimer L, Wiesinger H, Allgeier A, van den Bent MJ, Bogdahn U, van der Graaf W, Yun HJ, Gorlia T, Lacombe D, Brandes AA.

Ann Oncol. 2011 Sep;22(9):2144-9. doi: 10.1093/annonc/mdq729. Epub 2011 Feb 14.

12.

Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.

Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK.

Clin Cancer Res. 2007 Dec 1;13(23):7133-8.

13.

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2010 Jan;12(1):87-94. doi: 10.1093/neuonc/nop017. Epub 2009 Dec 14.

14.

Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.

Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD; North American Brain Tumor Consortium and the National Cancer Institute.

Clin Cancer Res. 2007 Dec 15;13(24):7401-6.

15.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M.

J Clin Oncol. 2007 Aug 10;25(23):3399-406. Epub 2007 Jul 2.

PMID:
17606975
16.

Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.

Rudek MA, New P, Mikkelsen T, Phuphanich S, Alavi JB, Nabors LB, Piantadosi S, Fisher JD, Grossman SA.

J Neurooncol. 2011 Nov;105(2):375-81. doi: 10.1007/s11060-011-0602-9. Epub 2011 May 6.

17.

A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.

Roché H, De Benedictis E, Cottura E, Govi S, Dalenc F, Locatelli A, Deslandres M, Zambetti M, Gladieff L, Messina M, Gianni L.

Clin Breast Cancer. 2012 Jun;12(3):167-74. doi: 10.1016/j.clbc.2012.03.009.

PMID:
22607766
18.

Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.

Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S.

Clin Cancer Res. 2003 Aug 1;9(8):2940-9.

19.

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA.

Neuro Oncol. 2010 Dec;12(12):1300-10. doi: 10.1093/neuonc/noq099. Epub 2010 Aug 17.

20.

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.

Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E; North Central Cancer Treatment Group.

J Neurooncol. 2009 Apr;92(2):165-75. doi: 10.1007/s11060-008-9749-4. Epub 2008 Dec 10.

Supplemental Content

Support Center